Melanoma | Clinical

November 24, 2021

BNT111, an immunotherapy agent under investigation in a phase 2 study, has been granted fast track designation by the FDA.

November 17, 2021

During the November 2021 Session of the American Society of Clinical Oncology Plenary Series, Michael B. Atkins, MD, presented data from the DREAMseq study, which compared 2 treatment sequences for advanced BRAF-mutant melanoma.

November 16, 2021

The CheckMate 204 study showed overall survival benefit of combination nivolumab/ipilimumab to patients with melanoma brain metastases.

November 12, 2021

Phase 2 results presented during the SITC Annual Meeting show that adding intratumoral BO-112 to pembrolizumab in patients with advanced melanoma can induce durable responses.

October 21, 2021

A fast-track designation was granted to a universal cancer vaccine in combination with checkpoint inhibitors. The vaccine, UV1, can be used in combination with either pembrolizumab or ipilimumab.

October 14, 2021

The combination had a 24-month OS rate of 80%.

September 23, 2021

Alrizomadlin, a MDM2-p53 inhibitor has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to prior immune-oncologic agents.

September 18, 2021

Compared with a placebo, adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death in patients with resected, high-risk stage II melanoma.

September 18, 2021

In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.

August 25, 2021

The FDA has accepted the biologics license application for tebentafusp and granted it priority review for the treatment of adult patients with HLA-A*02:01-positive metastatic uveal melanoma.